Advisors Preferred’s iShares Biotechnology ETF IBB Stock Holding History

Advisors Preferred’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-231	Closed	-$33.4K	–	230
2024 Q3	$33.4K	Buy	+231	New	+$33.4K	0.01%	182
2023 Q2	–	Sell	-123	Closed	-$16K	–	202
2023 Q1	$16K	Buy	+123	New	+$16.1K	0.01%	152
2021 Q4	–	Sell	-79,821	Closed	-$12.7M	–	198
2021 Q3	$12.7M	Buy	+79,821	New	+$13.4M	1.76%	17
2020 Q4	–	Sell	-209	Closed	-$28K	–	179
2020 Q3	$28K	Sell	209 -195,230	-100%	-$26.5M	0.01%	125
2020 Q2	$26.8M	Buy	195,439 +195,346	+210,049%	+$24.9M	7.5%	6
2020 Q1	$10K	Buy	+93	New	+$10.7K	0.01%	106
2015 Q3	–	Sell	-16,839	Closed	-$2.07M	–	222
2015 Q2	$2.07M	Sell	16,839 -2,451	-13%	-$293K	1.16%	28
2015 Q1	$2.21M	Sell	19,290 -4,485	-19%	-$495K	1.17%	27
2014 Q4	$2.4M	Buy	+23,775	New	+$2.31M	1.13%	25
2014 Q2	–	Sell	-18,792	Closed	-$1.48M	–	371
2014 Q1	$1.48M	Sell	18,792 -33,585	-64%	-$2.8M	0.68%	56
2013 Q4	$3.96M	Buy	+52,377	New	+$3.72M	2.19%	11

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Advisors Preferred's IBB Position: Q4 2024 in Review

Advisors Preferred sold out of iShares Biotechnology ETF (IBB) in Q4 2024, closing a stake of 231 shares — an estimated $33.4K sold.

Advisors Preferred first reported a position in IBB in Q4 2013 and held it in 11 quarters. The position peaked at $26.8M in Q2 2020. 875 funds tracked by Wall St. Rank hold IBB as of Q4 2024.

Advisors Preferred reported no remaining iShares Biotechnology ETF position as of Q4 2024 after selling out during the quarter.
Advisors Preferred sold 231 iShares Biotechnology ETF shares in Q4 2024, an estimated $33.4K.
Advisors Preferred first reported a position in iShares Biotechnology ETF in Q4 2013 and held it in 11 quarters.
Advisors Preferred's iShares Biotechnology ETF position peaked at $26.8M in Q2 2020.
875 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q4 2024.

Based on Advisors Preferred's 13F filing for Q4 2024, filed 28 Jan 2025.